(Source: GOV UK)
The National Institute for Biological Standards and Control (NIBSC) will play a key role in evaluating vaccines that have been developed for COVID-19.
The institute is one of seven partner laboratories that have been selected by CEPI (the Coalition for Epidemic Preparedness Innovations) to form a centralised laboratory to standardise the measurement of immune responses generated by multiple COVID-19 vaccine candidates. Samples from volunteers participating in phase I and phase II clinical trials will be tested in our labs as well as samples from preclinical studies.
Our scientists will be evaluating antibody responses and T-cell responses alongside other partner laboratories that are all using the same methods and biological reference materials. This will ensure that data are obtained in a consistent way so that the results for different vaccine candidates can be directly compared.
Read more on GOV UK
